Strategy

Molecular diagnostics (MDx) is revolutionizing the field of personalized medicine, particularly in the area of oncology where MDx can improve both healthcare outcomes and healthcare costs.

Using our extensive scientific expertise and our patented DNA-based methylation technology, MDxHealth focuses on providing high value MDx products that address significant unmet clinical needs and can be used in clinical laboratory testing.

Our mission is to develop and commercialize advanced molecular diagnostic products for personalized cancer treatment. This will be achieved with products that provide physicians with tools to aid in the diagnosis and or prognosis of cancers, aid in the physician’s ability to predict disease progression and or response to therapy.

We have an innovative and broad MDx product pipeline covering major cancer areas such as prostate, colon, lung and brain cancer.

We develop MDx products based on our patented DNA methylation platform integrating our proprietary DNA biomarkers. These assays deliver highly accurate analytical results and can be performed on a variety of sample types including formalin-fixed paraffin embedded (FFPE) tissue, fresh/frozen tissue, urine, plasma, serum, sputum, broncho-alveolar lavages and stool using commercially available PCR equipment.

We have two main product areas for which we use our leading methlylation platform:

1. Clinical Diagnostic products, which we develop, validate and commercialize independently to assist physicians in the assessment of cancer diagnosis and prognosis.
2. Pharmaco Molecular Diagnostic products, which we develop and validate in collaboration with pharmaceutical companies to accelerate clinical trials and regulatory approvals and improve treatment decisions.

MDxHealth has an ISO Certified Service lab in Liege, Belgium, and intends to offer its products in North-America through a CLIA Certified Service Lab.

Find out about our new strategy from our recent corporate presentation